Table 1.
Characteristics of COVID-19-Positive CARE Registry Participants at Enrollment by Self-Reported Use of Medications for Autoimmune Disease
| Participants at Enrollment | Participants with Follow-Up Around Day 30 | |||
|---|---|---|---|---|
| Taking Medications for Autoimmune Disease | Not Taking Medications for Autoimmune Disease | Taking Medications for Autoimmune Disease | Not Taking Medications for Autoimmune Disease | |
| (n=70) | (n=1,448) | (n=41) | (n=936) | |
| Age, years | ||||
| Mean (SD) | 46.9 (10.5) | 40.9 (11.9) | 48.6 (10.3) | 41.6 (11.8) |
| Median (IQR) | 45.5 (41–54) | 40 (32–49) | 48 (43–4) | 41 (33–50) |
| n (%) | n (%) | n (%) | n (%) | |
| Gender | ||||
| Female | 65 (92.9) | 1257 (86.8) | 39 (95.5) | 817 (87.3) |
| Education | ||||
| High school or less | 3 (2.86) | 229 (15.8) | 1 (2.4) | 139 (14.9) |
| Some college/2-year degree | 30 (42.8) | 553 (38.2) | 15 (36.6) | 338 (36.1) |
| 4-year college degree | 20 (28.6) | 326 (22.5) | 14 (34.2) | 233 (24.9) |
| >4-year college degree | 15 (21.4) | 304 (21.0) | 10 (24.4) | 213 (22.8) |
| Race | ||||
| Black or African American | 6 (8.6) | 85 (5.87) | 3 (7.3) | 54 (5.8) |
| White | 58 (82.9) | 1,141 (78.8) | 36 (87.8) | 765 (81.7) |
| Other | 6 (8.5) | 222 (5.3) | 1 (2.4) | 117 (12.5) |
| Ethnicity | ||||
| Hispanic or Latino | 5 (7.2) | 228 (15.8) | 5 (12.2) | 142 (15.2) |
| BMI group | ||||
| Normal (<25) | 13 (18.6) | 352 (24.3) | 9 (22.0) | 214 (22.9) |
| Overweight (25–30) | 17 (24.3) | 366 (25.3) | 11 (26.8) | 244 (26.1) |
| Obese (≥30) | 38 (54.3) | 683 (47.7) | 20 (48.5) | 458 (49.0) |
| Medical history | ||||
| Smoker | 1 (1.4) | 13 (0.9) | 0 (0.0) | 88 (9.4) |
| Cardiovascular Disease (incl. heart disease, stroke) | 5 (7.14) | 52 (3.6) | 3 (7.3) | 36 (3.9) |
| Taking Medication for Diabetes | 9 (12.9) | 93 (6.4) | 5 (12.2) | 61 (6.5) |
| Taking Medication for Hypertension | 21 (30.0) | 240 (16.6) | 9 (22.0) | 144 (15.4) |
| Taking Medication for Lung Disease | 10 (14.3) | 87 (6.0) | 5 (12.2) | 62 (6.6) |
| Hospitalized Due to Likely COVID-19 Related | 2 (2.9) | 18 (1.2) | 1 (2.4) | 8 (0.9) |
| Incentivized | 35 (50.0) | 793 (54.8) | 28 (68.3) | 666 (71.2) |
| Distribution of Symptoms at Enrollment | ||||
| N of symptoms | ||||
| Mean (SD) | 7.3 (3.1) | 6.6 (3.3) | 7.0 (3.1) | 6.8 (3.2) |
| Median (IQR) | 7 (5-9) | 7 (4-9) | 7 (5–9) | 9 (7–11) |
| Severity score* | ||||
| Mean (SD) | 12.1 (6.4) | 10.9 (6.6) | 11.8 (6.4) | 11.3 (6.4) |
| Median (IQR) | 12 (7-17) | 10 (6-15) | 11 (7–17) | 11 (6–15) |
Notes: *Severity score was calculated as the sum of individual symptom severity across 15 symptoms (0=absent; 1=very mild/mild; 2=moderate; 3=severe).
Abbreviations: SD, standard deviation; IQR, interquartile range; BMI, body mass index.